Skip to content

VoiceLove Digital Therapy for Delirium in the ICU

Feasibility of VoiceLove Digital Therapy for Delirium Management in ICU Patients: A Pilot Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07218484
Enrollment
15
Registered
2025-10-20
Start date
2025-08-21
Completion date
2026-01-31
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Keywords

delirium, intensive care unit, cognitive dysfunction, confusion

Brief summary

The study is a single-center, single-arm, prospective trial to evaluate the feasibility, safety, and acceptability of VoiceLOVE digital therapy for the management of delirium in surgical ICU patients. 15 participants will be enrolled. The study expects that 70% of participants will complete 20 -25 minutes of the VoiceLOVE digital therapy. Descriptive statistics will be used to summarize the findings. The intent is that this study will provide information for a larger, subsequent clinical trial of surgical ICU patients who are at risk for delirium.

Detailed description

VoiceLove digital therapy includes voice recordings of the participant's loved one delivered at the bedside via a smartphone attached to the bed. The VoiceLove digital therapy will be delivered in the morning and in the evening and will play for 20-25 minutes each session. Participants will have a pre-operative visit, 3 consecutive intervention visits with vital signs assessment, 7 days of assessments of Confusion Assessment Methods (CAM)-ICU (morning and evening), and 7 days of a Richmond Agitation-Sedation Scale assessment. The participant will provide an assessment of the acceptability of the VoiceLove digital therapy using a system usability scale score at the end of their participation in the study.

Interventions

BEHAVIORALVoiceLove therapy

VoiceLove digital interventions represent voice recordings, specifically, (i) Reorientation messages, and (ii) general communication domain calming and encouraging voice messages recorded in familiar voices from family and friends. Families will be guided to record and deliver Reorientation messages, that can be played to the patient.

Sponsors

The Methodist Hospital Research Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The study is a single-center, single-arm, prospective trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Men and women aged ≥18 years admitted to the hospital after major surgery (elective or non-elective) require a hospital stay of at least five days following surgery, including an ICU stay for at least three days after the surgical procedure 2. At risk of delirium, as per ICU delirium risk score or existing diagnosis 3. Family members or caregivers involved in patient care at least 18 years of age. 4. Clinical team members caring for the patients

Exclusion criteria

* Patients in the ICU who have 1. a history of severe mental illness, 2. admission for a drug overdose, 3. severe vertigo, 4. a history of severe postoperative nausea and vomiting, 5. hearing or visual impairments, 6. preexisting severe dementia (Montreal Cognitive Assessment Score \<15), 7. neurological surgeries.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of VoiceLove digital therapy use by participants in the ICUBaseline to day 370% of participants complete two 25-minute sessions of VoiceLove digital therapy per day for 3 days

Secondary

MeasureTime frameDescription
Change in peripheral arterial oxygen saturation (SpO2) after VoiceLove digital therapyStart of VoiceLove digital therapy to 25 minutes of session on day 1, on day 2, and on day 3.Mean change in SpO2 during VoiceLove digital therapy sessions
Change in blood pressure after VoiceLove digital therapyStart of Voice Love digital therapy to 25 minutes of session on day 1, on day 2, and on day 3.Mean change in blood pressure during VoiceLove digital therapy sessions
Change in respiratory rate after VoiceLove digital therapyStart of VoiceLove digital therapy to 25 minutes of session on day 1, on day 2, and on day 3.Mean change in respiratory rate during VoiceLove digital therapy sessions
Change in heart rate after VoiceLove digital therapyStart of VoiceLove digital therapy to 25 minutes of session on day 1, on day 2, and on day 3.Mean change in heart rate during VoiceLove digital therapy sessions

Other

MeasureTime frameDescription
Delirium daysFrom start of VoiceLove digital therapy sessions at baseline through study completion, day 7Total number of delirium-positive days
Acceptability of VoiceLove digital therapyDay of Hospital Discharge, Visit 8Proportion of participants with a system usability scale score \>35
Family satisfaction surveyICU day 3, Visit 4Total score of system usability survey for family or caregiver member
Readmissions to the ICU during the hospital stayFrom last day in ICU to a return to ICU prior to hospital discharge, Visit 8Total number of readmissions to the ICU
Delirium onset during the studyFrom start of VoiceLove digital therapy sessions at baseline through study completion, day 7Proportion of participants with delirium onset
Hypoactive deliriumFrom start of VoiceLove digital therapy sessions at baseline through study completion, day 7Proportion of participants with hypoactive delirium
Hyperactive deliriumFrom start of VoiceLove digital therapy sessions at baseline through study completion, day 7Proportion of participants with hyperactive delirium
Delirium severityFrom start of VoiceLove digital therapy sessions at baseline through study completion, day 7Proportion of participants with mild, moderate, or severe delirium

Countries

United States

Contacts

Primary ContactDarrel Cleere, BSN RN CCRP
dwcleere@houstonmethodist.org713-441-6232
Backup ContactShondra Word
sword@houstonmethodist.org713-441-5122

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026